With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
Low levels of a certain thyroid hormone may have broader implications for newly diagnosed patients with multiple myeloma (MM), say study results.
According to the single-center retrospective study of 200 patients, low T3 syndrome could potentially help predict survival outcomes among these patients, with multivariate analyses showing that the syndrome was an independent factor associated with both overall (OS) and progression-free survival (PFS). The researchers noted that their findings are the first, to their knowledge, to draw a connection between low T3 syndrome and survival among patients with MM.
With survival of MM ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance. The researchers say their findings indicate that low T3 levels—an easily measured hormone—may aid in risk stratification for these patients.
The group observed significantly worse OS (34 months vs 85 months) and PFS (20 months vs 52 months) among the 80 patients (39.8%) with low T3 syndrome at baseline compared with patients without the syndrome.
“As to why low T3 syndrome at baseline was strongly associated with survival in MM patients, we suggested that it was probably due to the correlations of low T3 syndrome with not one but several known prognostic factors,” explained the researchers.
They added, “the higher inflammation state, serum β2-MG, and creatinine levels, lower hemoglobin and albumin levels, and more advanced ISS [International staging system] and [Revised]-ISS stages in low T3 syndrome patients in this study suggested that elevated inflammation, malnutrition, anemia, renal dysfunction, and more advanced disease severity stage probably could explain the predictive ability of low T3 syndrome for the prognosis in MM.”
Subgroup analyses showed that low T3 syndrome had poor implications for survival regardless of whether or not the patient received novel treatments (bortezomib and/or lenalidomide-based treatment) and for patients not receiving autologous stem cell transplantation.
The researchers found that serum FT3 was predictive of mortality during the entire follow-up period and had positive correlations with albumin and hemoglobin levels and had negative correlations with β2-MG, creatinine, neutrophil/lymphocyte ratio, and (neutrophil+monocyte)/lymphocyte ratio. The researchers explained that these findings suggest multiple factors are likely connected to low T3 syndrome in the disease.
“[Receiver operator characteristic curve] analyses showed that FT3 was a significant predictor for both death and one-year death. The optimal cut-off values of FT3 for predicting death and one-year death were 2.36 pg/mL and 2.34 pg/mL, respectively,” detailed the researchers. “Both above values were close to the lower limit of the FT3 normal range (2.3 pg/mL), which also was the value used to define low T3 syndrome in this study.”
FT4 and thyrotropin were also included in ROC analyses, although FT3 had the largest area under the curve.
Reference
Pan Q, Jian Y, Zhang Y, et al. The association between low T3 syndrome and survival in patients with newly diagnosed multiple myeloma: a retrospective study. Technol Cancer Res. Published online April 20, 2020. doi:10.1177/15330338221094422
CAR T Proves Effective and Safe for Refractory Multiple Myeloma
May 15th 2024Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.
Read More
Study Urges Personalized Care to Boost Quality of Life in Patients With MM
April 11th 2024Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.
Read More
FDA Approves Cilta-Cel for Earlier Treatment of RRMM
April 6th 2024Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More